News for GRFS Stock

Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies Grifols 2023 Annual Report on Form 20-F filed with the SEC Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening Grifols announces positive topline phase 3 fibrinogen clinical trial results Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022 Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation Grifols partners with Feeding America® to help address hunger in the U.S. Grifols signs global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS,' extends category leadership for sixth consecutive year Grifols acquires its first plasma donation center in Canada Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030 Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021 Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19 Grifols installs first-ever DG Reader Net analyzer in North America Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins Grifols fosters world's first scientific journal specialized in blood plasma Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS' for fifth consecutive year Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19 Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S. Grifols installs first-ever DG Reader Net analyzer in North America Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins Grifols fosters world's first scientific journal specialized in blood plasma Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS' for fifth consecutive year Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19 The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies Grifols partners with TRC Healthcare to streamline intravenous compounding education Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19 Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S. Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome Grifols delivers first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials Grifols acquires 10% stake in Bloodbuy, cloud-based marketplace for blood products Results of Grifols' AMBAR clinical trial published in Alzheimer's & Dementia: The Journal of The Alzheimer's Association Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million